Cargando…
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
BACKGROUND: Uterine fibroids are one of the most common neoplasms found among women globally, with a prevalence of approximately 11 million women in the United States alone. The morbidity of this common disease is significant because it is the leading cause of hysterectomy and causes significant fun...
Autores principales: | Al-Hendy, Ayman, Bradley, Linda, Owens, Charlotte D., Wang, Hui, Barnhart, Kurt T., Feinberg, Eve, Schlaff, William D., Puscheck, Elizabeth E., Wang, Alice, Gillispie, Veronica, Hurtado, Sandra, Muneyyirci-Delale, Ozgul, Archer, David F., Carr, Bruce R., Simon, James A., Stewart, Elizabeth A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800453/ https://www.ncbi.nlm.nih.gov/pubmed/32702363 http://dx.doi.org/10.1016/j.ajog.2020.07.032 |
Ejemplares similares
-
Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021) -
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020) -
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids
por: Stewart, Elizabeth A., et al.
Publicado: (2022) -
Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2
por: Gillispie, V., et al.
Publicado: (2020) -
Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis
por: Muhammad, Juliawati, et al.
Publicado: (2022)